AtaiBeckley
Berlin · Founded 2018
About AtaiBeckley
AtaiBeckley is a biopharmaceutical company that develops rapid-acting mental-health therapies. Its pipeline includes an intranasal mebufotenin benzoate candidate (BPL-003) for treatment-resistant depression, a DMT buccal film, and an oral R-MDMA compound . The company conducts clinical trials and drug development in neuropsychiatric conditions.
Company Facts
- Founded: 2018
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $796.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2025)
- Ticker: nasdaq:ATAI
- Website: ataibeckley.com
- Phone: +31 20 793 2536
Industries & Categories
Biotechnology, Life Science, Mental Health, Neuroscience, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/ataibeckley-81921 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.